Raymond James Financial
TNXP icon

Raymond James Financial’s Tonix Pharmaceuticals TNXP Stock Holding History

Raymond James Financial’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7
Closed -$252 – 6629
2025
Q2 		$252 Buy
+7
New +$183 ﹤0.01% 6756

Other funds holding TNXP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Fund Management (CFM)
Capital Fund Management (CFM) Paris, France $22.1B AUM 20.49% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SPS
Susquehanna Portfolio Strategies Bala Cynwyd, Pennsylvania $6.73B AUM 45.57% 1-Year Est. Return

Raymond James Financial's TNXP Position: Q3 2025 in Review

Raymond James Financial sold out of Tonix Pharmaceuticals (TNXP) in Q3 2025, closing a stake of 7 shares — an estimated $252 sold.

Raymond James Financial first reported a position in TNXP in Q2 2025 and held it in 1 quarter. The position peaked at $252 in Q2 2025. 60 funds tracked by Wall St. Rank hold TNXP as of Q3 2025.

  • Raymond James Financial reported no remaining Tonix Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 7 Tonix Pharmaceuticals shares in Q3 2025, an estimated $252.
  • Raymond James Financial first reported a position in Tonix Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Tonix Pharmaceuticals position peaked at $252 in Q2 2025.
  • 60 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.